Best GLP-1 Weight Loss Medication for Men: Semaglutide vs Tirzepatide
Both semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) help men lose double-digit body-weight percentages, but one is consistently faster and deeper. See how the two injectable GLP-1 medicines compare and learn which factors-age, BMI, side-effects, and out-of-pocket cost-should drive your decision.
Semaglutide and tirzepatide are weekly prescription injections that curb appetite, slow stomach emptying, and improve blood-sugar control, leading to average weight-loss of 15 % and 21 %, respectively, in large clinical trials. For most men, tirzepatide removes more pounds, but semaglutide can be a better fit if you need a milder starting dose, have gallbladder issues, or prefer more years of safety data. Talk with a licensed provider to weigh efficacy against side-effects, insurance coverage, and monthly cost before choosing a GLP-1.
- Men in the STEP-1 trial lost an average 14.9 % of their starting weight on semaglutide 2.4 mg over 68 weeks, compared with 2.4 % on placebo.(nejm.org)
- The SURMOUNT-1 study showed 20.9 % mean weight loss with tirzepatide 15 mg after 72 weeks, versus 3.1 % for placebo.(nejm.org)
- Nausea was reported by 44 % of Wegovy users and 32 % of Zepbound users in pivotal trials, making stomach upset the top reason men stop therapy early.(dailymed.nlm.nih.gov)
- Rx.com offers compounded semaglutide from $99/month and compounded tirzepatide from $149/month with a 12-month plan that includes the online doctor visit.
- Zepbound’s list price is $1,059.87 per four-week pen, about 20 % lower than the current $1,349.02 WAC for Wegovy injections.(investor.lilly.com)
What GLP-1 Weight-Loss Drugs Are
GLP-1 medicines are injectable or oral drugs that mimic the gut hormone glucagon-like peptide-1 to reduce appetite and slow gastric emptying, leading to fewer calories consumed. Semaglutide is a single GLP-1 receptor agonist sold for diabetes as Ozempic and for obesity as Wegovy. Tirzepatide is a dual GIP/GLP-1 agonist marketed as Mounjaro for diabetes and Zepbound for weight management.
Both were cleared by the FDA for adults with a body-mass index (BMI) ≥ 30 kg/m², or ≥ 27 kg/m² plus a weight-related condition such as hypertension or sleep apnea. Men meet those criteria at a lower absolute weight than women because the BMI equation adjusts only for height, not sex.
How Semaglutide and Tirzepatide Help Men Lose Weight
The two drugs share four appetite-suppressing actions but tirzepatide adds a fifth by stimulating GIP receptors in fat tissue, which may further boost calorie burn. Both:
- Increase post-meal satiety: You feel full sooner during meals.
- Slow stomach emptying: Food stays longer in the stomach, lowering hunger hormones.
- Lower fasting glucose: Stable blood sugar prevents cravings.
- Enhance insulin secretion: Better insulin timing reduces fat storage.
- (Tirzepatide only) Activates GIP receptors: Early data suggest additional energy expenditure and brown-fat activation.(pmc.ncbi.nlm.nih.gov)
| Mechanism | Semaglutide | Tirzepatide |
|---|---|---|
| GLP-1 receptor activation | Yes | Yes |
| GIP receptor activation | No | Yes |
| Typical dose range for weight loss | 0.25→2.4 mg | 2.5→15 mg |
| FDA obesity approval year | 2021 | 2023 |
Head-to-Head Efficacy: How Much Weight Men Lose
Across trials, tirzepatide consistently delivers 4–7 percentage-points more weight loss than semaglutide at one year, and men benefit as much as women. While no study has randomized semaglutide and tirzepatide against each other, comparing placebo-adjusted results provides a clear signal.
| Trial (Population) | Drug & Dose | Weeks | Mean % Weight Loss |
|---|---|---|---|
| STEP-1 (n = 1,961, 38 % men)(nejm.org) | Semaglutide 2.4 mg | 68 | -14.9 % |
| SURMOUNT-1 (n = 2,539, 35 % men)(nejm.org) | Tirzepatide 15 mg | 72 | -20.9 % |
| STEP-1 Male Subgroup(pmc.ncbi.nlm.nih.gov) | Semaglutide 2.4 mg | 68 | -13.3 % |
| SURMOUNT-J Male Subgroup (Japan)(pubmed.ncbi.nlm.nih.gov) | Tirzepatide 15 mg | 72 | -18.1 % |
Speed matters for motivation. In SURMOUNT-1, half of patients on tirzepatide 10–15 mg lost ≥ 10 % of their weight by week 24, a milestone semaglutide usually reaches near week 40.
Side-Effects and Safety Differences
Both drugs cause mainly gastrointestinal side-effects, but semaglutide triggers nausea slightly more often and tirzepatide causes more diarrhea and fatigue. Serious risks-pancreatitis, gallstones, thyroid C-cell tumors in rodents-are class warnings applicable to both.
| Adverse Event (≥ 5 %) | Wegovy 2.4 mg | Zepbound 15 mg |
|---|---|---|
| Nausea | 44 % | 32 % |
| Diarrhea | 30 % | 33 % |
| Vomiting | 25 % | 18 % |
| Constipation | 24 % | 24 % |
| Fatigue | 8 % | 12 % |
Across pivotal trials, 4.3 % of semaglutide patients and 6.7 % of tirzepatide patients stopped because of side-effects.(dailymed.nlm.nih.gov)
Tips to minimize stomach issues:
Meal size and timing: Eat four to five small protein-rich meals instead of two large ones. Avoid trigger foods: High-fat fried items and carbonated drinks worsen nausea. Hydrate strategically: Sip electrolyte water between, not during, meals. For more tactics see our detailed nausea guide.
Cost, Insurance, and Rx.com Savings
Sticker shock is real: brand-name GLP-1 list prices top $1,000 per month, and many commercial plans still exclude obesity drugs.
| Option | Monthly price (Oct 2026) | Includes |
|---|---|---|
| Rx.com compounded semaglutide 12-month plan | $99 | Medication, provider visit, all doses, shipping |
| Rx.com compounded tirzepatide 12-month plan | $149 | Medication, provider visit, all doses, shipping |
| Wegovy list price (Novo Nordisk) | $1,349.02 | One 4-week pen kit |
| Zepbound list price (Eli Lilly) | $1,059.87 | One 4-week pen kit |
| NovoCare savings card | $0–$500 | Commercial insurance only, 12-month limit |
| LillyDirect self-pay offer | $299–$550 | 2.5–15 mg pens, supply dependent |
Compare cash prices at local pharmacies on Rx.com with a free discount card. Even if your insurance covers the drug, you can ask the pharmacist to run the Rx.com card as a secondary claim and choose the lower price.
How to Choose the Right GLP-1
Tirzepatide is the front-runner for speed and magnitude, but semaglutide may win on cost, track record, or GI tolerability. Use the checklist below to see where you fit.
Should I start semaglutide or tirzepatide?
Check the column that fits your situation:
✅ Semaglutide may be enough
- BMI 27–34 kg/m² and goal < 15 % weight loss
- History of sensitive stomach or gallbladder issues
- Need lower upfront cost ($99/month on Rx.com)
- Prefer five years of post-approval safety data
🏥 Tirzepatide likely warranted
- BMI ≥ 35 kg/m² or goal ≥ 20 % weight loss
- Past semaglutide plateau or regain
- Prediabetes or strong family history of diabetes
- Able to afford $149/month compounded or brand copay
Transitioning from one GLP-1 to another? See our step-by-step guide on switching safely.
🚨 When to Contact Your Healthcare Provider
Contact your doctor immediately if you experience any of the following:
- Severe, persistent abdominal pain - could signal pancreatitis.
- Yellowing of skin or eyes - potential gallbladder blockage.
- Rapid heartbeat at rest - may indicate heart-rate increase beyond normal.
- Signs of dehydration (dizziness, dark urine) - from prolonged vomiting or diarrhea.
- Difficulty swallowing or neck swelling - possible thyroid mass, especially if you have a family history of medullary thyroid carcinoma.
- Severe allergic reaction (hives, swelling, trouble breathing).
- Vision changes in men with type 2 diabetes - could signal worsening retinopathy.
- Thoughts of self-harm or severe mood changes - rare but reported; call 911 or text 988 if in crisis.
Scientific References
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021.
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022.
- Wegovy (semaglutide) Prescribing Information. Novo Nordisk; revised 2026.
- Zepbound (tirzepatide) Prescribing Information. Eli Lilly; revised 2026.
- Eli Lilly and Company. FDA approves Zepbound for chronic weight management. Press release 2023.
- Liang Y et al. Sex differences in the efficacy of GLP-1 receptor agonists for weight reduction: a systematic review and meta-analysis. Obes Rev. 2025.
Frequently Asked Questions
Is tirzepatide safe for long-term use in men?
Clinical trials follow participants for up to two years and show sustained weight loss with no new safety signals. Post-marketing studies are ongoing, so men on tirzepatide should keep regular follow-ups and lab checks.
Can I drink alcohol while on semaglutide or tirzepatide?
Moderate alcohol does not interact directly, but both drugs slow gastric emptying, which can heighten nausea and lower blood sugar. Limit intake to one to two drinks and never drink on an empty stomach.
Do GLP-1 drugs lower testosterone in men?
No evidence shows semaglutide or tirzepatide reduce testosterone. Weight loss itself may improve testosterone levels by decreasing visceral fat.
Which injection needle is less painful?
Both pens use 32- to 34-gauge needles that most men describe as a quick pinch. Zepbound’s KwikPen auto-retracts, which some users find easier than the Wegovy pre-filled pen.
How soon will I see results on tirzepatide?
Men often notice 5 % weight loss by week 12 at 7.5 mg or higher, faster than the typical 16–20 weeks required with semaglutide escalation.
Will insurance cover compounded semaglutide or tirzepatide?
No-insurance plans reimburse only FDA-approved brands. Compounded medications are cash-pay, which is why programs like Rx.com’s offer multi-month pricing.
What happens if the drug is out of stock?
If pharmacies cannot fill brand prescriptions, ask your prescriber about temporary dose adjustments, pharmacy transfers, or a switch to compounded medication through a 503A pharmacy.
